Dr. Adam Smith describes how his organization, has evaluated optical genome mapping as a first-line test for hematologic malignancies specifically focusing on acute myeloid leukemia and replacing a legacy eosinophilic leukemia FISH panel.

This insightful Bionano-IPM webinar, offers a unique, combined perspective of a pathologist, Dr. Kanagal-Shamanna, and an oncologist, Dr. Garcia-Manero, on the utility of OGM in Myelodysplastic Syndromes (MDS), a type of hematologic malignancy, based on leading research conducted by their groups at the MD Anderson Cancer Center.